Leidi.com Lei Jianping July 19
Shanghai Baiying Biotechnology Co., Ltd. (abbreviation: "Baiying Bio") recently submitted a prospectus and is preparing to list on the Shenzhen Stock Exchange's Growth Enterprise Market.
Baiying Biotech plans to raise 1.05 billion yuan, of which 302 million yuan will be used for the Shanghai R&D center project, 460 million yuan will be used for the Jiangsu production base construction project, and 300 million yuan will be used to supplement working capital.
Annual revenue 260 million
Baiying Bio is a CRO company focusing on antibody expression and antibody discovery and optimization. It mainly provides customized technical services such as antibody expression, antibody discovery and optimization for biopharmaceutical companies. Baiying Bio is also engaged in the production and sales of a small amount of recombinant antibodies, recombinant proteins and other scientific research reagent products.
According to the prospectus, Baiying Bio's revenue in 2020, 2021, and 2022 will be 68.723 million yuan, 167 million yuan, and 260 million yuan;
At the end of each reporting period, the aging of accounts receivable is mainly within 1 year, and the net book value of accounts receivable of the company is 18.2525 million, 51.3209 million and 78.8034 million respectively, accounting for 29.76%, 32.02% and 13.09% of the current assets at the end of each period.
Cha Changchun controls 40% of the shares
As of the signing date of this prospectus, Zha Changchun directly holds 11.9314 million shares of Baiying Bio, with a shareholding ratio of 20.93%, and is the controlling shareholder of the company; Zha Changchun holds 46.42% of the partnership shares of Taizhou Zhiben and serves as the executive partner. Taizhou Zhiben holds 10.7828 million shares of Baiying Bio, with a shareholding ratio of 18.92%.
Therefore, Zha Changchun indirectly controls 18.92% of the equity of Baiying Bio through Taizhou Zhiben; in summary, Zha Changchun controls a total of 39.85% of Baiying Bio, and is the actual controller of the company.
Before the IPO, Cheng Qianwen held 7.27%, Ningbo Fayu held 6.12%, Zibo Zhaofeng held 5.39%, Ningbo Higgs held 5.05%, Shanghai Kunwan held 4.04%, Taizhou Zhizhen, Taizhou Zhitong, Taizhou Zhiheng, Taizhou Zhihe each held 2.69%, Suzhou Jifeng, Ningbo Fuqi, and Hangzhou Tiger held 1.8% respectively;
Wuhu Hengsheng holds 1.54%, Haitong Ventures holds 1.4%, Jiangsu High-tech Investment holds 1.12%, Yue Shi Jinglang holds 0.98%, Nanjing Cornerstone, Wuhu Cornerstone, Ma'anshan Cornerstone, Yangtze River Delta Jiaolong, Cao Hong, and Gongqingcheng Chengshu Phase 5 hold 0.9% respectively, Nanjing Gaorong holds 0.68%, Nanjing Tianhui holds 0.66%, and Chen Wei and Zhao Yan respectively hold shares 0.65%, Gongqingcheng Chengshu Phase 7 holds 0.6%, October Dihua holds 0.56%, and Sanya Gaorong holds 0.23%.
The investors of Nanjing Gaorong include Xiaomi Technology Co., Ltd. and Linzhi Yongchuang Information Technology Co., Ltd., each holding a 5.42% share; Chen Shengqiang holds a 0.27% share.
After the IPO, Cha Changchun holds 15.7%, Taizhou Zhiben holds 14.19%, Cheng Qianwen holds 5.45%, Ningbo Fayu holds 4.59%, Zibo Zhaofeng holds 4.04%, Ningbo Higgs holds 3.79%, and Shanghai Kunwan holds 3.03%;
Taizhou Zhizhen, Taizhou Zhitong, Taizhou Zhiheng, and Taizhou Zhihe each hold 2.02% of the shares, Suzhou Jifeng, Ningbo Fuqi, and Hangzhou Tiger each hold 1.35% of the shares;
Wuhu Hengsheng holds 1.16%, Haitong Ventures holds 1.05%, Jiangsu High-tech Investment holds 0.84%, Yueshi Jinglang holds 0.74%, Nanjing Cornerstone, Wuhu Cornerstone, Maanshan Cornerstone, and Yangtze River Delta Jiaolong hold 0.68% respectively, and Cao Hong and Gongqingcheng Chengshu Phase 5 hold 0.67% respectively;
Nanjing Gaorong holds 0.51%, Nanjing Tianhui holds 0.49%, Chen Wei and Zhao Yan each hold 0.48%, Gongqingcheng Chengshu Phase 7 holds 0.45%, and October Dihua holds 0.42%.
———————————————
Lei Di was founded by Lei Jianping, a media person. If you reprint, please indicate the source.
